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Abstract
Background: Detection of plasma cell dyscrasias
(PCD) requires screening of serum and urine for
monoclonal proteins. Several studies have demon-
strated increased sensitivity and specificity when
measurement of serum free light chain (SFLC) is part
of the screening protocol. In addition, omission of
immunofixation (IFE) in the standard work-up that
includes SFLC assay has been proposed. This study
attempts to define the role of the SFLC assay in a
screening strategy limited to serum only. It compares
outcomes to a serum-only screening strategy that
omits serum IFE.
Methods: Serum from 691 patients was analysed for
the presence of monoclonal protein using standard
serum IFE, serum protein electrophoresis (SPE) and
measurement of SFLC. Data were analysed retro-
spectively.
Results: Specificity and sensitivity of abnormal SFLC-
ratios for the detection of monoclonal protein using
IFE were 96% and 41%, respectively. Eighteen pat-
ients with negative monospecific and Bence Jones
IFE, but abnormal SFLC-ratios were identified. In most
cases, this could be attributed to kidney and inflam-
matory disease or haematological disorders. In four
cases, this resulted in further diagnostic investigation
and light chain disease was later detected in two
cases. Light chain disease was confirmed in one case
but not confirmed in the other patient. In 14 patients,
Bence Jones IFE was negative, although the concen-
trations of SFLC suggested the presence of monoclo-
nal Bence Jones protein at concentrations detectable
by IFE. Thus, either the anti-serum failed at detection,
there was polymerisation of the free light chains or
the SFLC assay overestimated protein concentrations.
Simulating a work-up that included IFE only if abnor-
malities were detected by SPE or the SFLC assay
would have resulted in 26% fewer IFEs being per-
formed, but three patients with monoclonal proteins
by IFE would have been missed.
Conclusions: Abnormal SFLC concentrations are
neither sensitive nor specific for the detection of
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monoclonal proteins by IFE. Not all PCD are accom-
panied by excessive production of SFLC, and several
other conditions, such as renal disease are associated
with increased SFLC concentrations. An abnormal
SFLC-ratio is a specific marker for PCD, and occurs
primarily in patients with haematological disease. If
renal and inflammatory diseases are excluded, this
should prompt further diagnostic investigation.
Screening of serum without performing an IFE as a
standard procedure leads to a reduction of sensitivity
when compared to screening of serum that includes
IFE.
Clin Chem Lab Med 2009;47:1109–15.
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Introduction
Detection and monitoring of patients with plasma cell
dyscrasias (PCD), such as intact immunoglobulin
myeloma (IIMM), non-secretory myeloma (NSMM),
light-chain multiple myeloma (LCMM) and AL amy-
loidosis (AL) requires laborious work-up including
serum protein electrophoresis (SPE) and immunofixa-
tion (IFE) of serum and urine (1, 2). Although this pro-
cedure allows detection of LCMM, quantitation of
serum free light chain (SFLC) was difficult and prone
to error, especially due to non-specific binding of
intact immunoglobulins (3). Recently, a turbidimetric
assay became available allowing for more specific
detection and quantitation of SFLC in serum and urine
(4).
Quantitation of SFLC is recommended for patients
with multiple myeloma (5), and patients with AL (6)
because it appears to offer advantages in diagnosis
and follow-up. However, there is no consensus on a
safe and cost effective strategy to screen patients with
suspected PCD (7–15). Recently, it has been suggest-
ed to replace screening of urine for FLC by quantita-
tion of FLC in serum as the standard screening
procedure; reducing turn-around time but increasing
costs (7, 8, 12, 13). Some have even suggested omit-
ting IFE (11, 14). Although screening of urine and
serum remains the gold standard, offering the highest
sensitivity and specificity for the detection of mono-
clonal gammopathy (16), screening of serum only is
common practise because collection of urine is often
forgotten. For example, recent studies showed that
only 35%–40% of serum samples were accompanied
by urine samples (7, 17). Therefore, establishing a
standardised screening procedure that depends on
1110 Böer and Deufel: Evaluation of screening algorithms for monoclonal gammopathies
Article in press - uncorrected proof
urine IFE is difficult. In addition, handling one sample
only is cost- and time-saving, and reduces labour
input (7). We chose a PCD screening strategy using
serum only, and performed SPE, screening IFE with
pentavalent anti-serum and, if positive, a monospe-
cific IFE. We attempted to elicit the role of the ‘‘Free-
lite’’ SFLC assay in this modified work-up. Sera from
two of three patients, who were later diagnosed with
PCD and who were positive by the SFLC assay but
negative by Bence Jones IFE, were studied more
thoroughly.
In a high-throughput laboratory environment, reduc-
tion of hands-on-time by eliminating manual methods
from the standard workflow is desirable. In the case
of PCD screening, this applies to the standard serum
IFE, even though it is considered to be the gold stan-
dard. This approach has been tested recently (11, 14,
16). In one report, it was found to be suitable for PCD
screening, but except for these studies there has been
no validation of this approach (11). Therefore, the use
of a screening strategy that omits IFE and is similar




We retrospectively reviewed all data from 691 patient serum
samples that were initially screened for suspected mono-
clonal gammopathy (monoclonal screening programme)
between August 2006 and September 2007 in a hospital pop-
ulation (requesting wards: 190 haematology/oncology, 113
nephrology, 99 neurology, 38 gastroenterology, 37 cardiol-
ogy, 30 rheumatology, 30 dermatology, 23 endrocrinology,
21 infectious diseases, 110 other patients). Mean age of the
patients was 65 years wstandard deviation (SD): 14.4 yearsx
with 313 females and 378 males. This population resembles
a setting in which samples from unselected patients with
clinical suspicion of monoclonal gammopathy are screened.
It includes patients with other diseases that are known to
influence SFLC concentrations. For patients sampled repeat-
edly in the monoclonal gammopathy screening programme
during this time, only the first sample was included in the
analysis. On request from the ordering physician, the labo-
ratory offers SPE which is evaluated for the presence of M-
protein bands that is independent of the monoclonal
screening programme (see standard work-up). In addition to
the 691 patients who were screened in the monoclonal
screening programme, 10,818 SPEs were performed for
other patients during the study period.
Technical procedures
SPE was performed using capillary zone electrophoresis
(Paragon capillary zone electrophoresis 2000; Beckman
Coulter, Krefeld, Germany). IFE was performed using the
Hydragel 4 IF Kit (Sebia, Fulda, Germany) with either pen-
tavalent antiserum (Sebia) or monospecific IFE (specificity: k
free and bound light chains, l free and bound light chains,
a, g and m heavy chains). Bence Jones IFE in serum was
performed using the Hydragel Bence Jones Kit (Sebia). The
manufacturer of the assay states that sensitivity of the Bence
Jones IFE is at least 50 mg/L in urine, or 150 mg/L in serum
since a 1:3 dilution is performed to minimise background for
any monoclonal k- or l-FLC. However, it may be lower for
individual monoclonal k- or l-FLC. Therefore, a general
detection limit of 150 mg/L in serum was assumed in this
analysis. k- and l-SFLC were quantified using the ‘‘Freelite’’
assay (The Binding Site, Schwetzingen, Germany) with the
BNII (Dade Behring, Marburg, Germany) nephelometric
analyser according to the manufacturer’s instructions.
Reference intervals were -19.4 mg/L for k-SFLC, -26.3 for
l-SFLC and 0.26–1.65 for the SFLC-ratio. Because there is no
pathology associated with decreased SFLC-concentrations
we used only an upper reference limit. All samples were
initially measured at a 1:100 dilution to minimise re-runs,
and SFLC concentrations below 10 mg/L were reported as
-10 mg/L. We modified the manufacturer’s recommenda-
tions and re-runs were performed at dilutions of 1:2000,
1:40,000 and 1:160,000 dilutions to minimise reagent
consumption.
Imprecision of the assay was 11.6% (l-SFLC, mean:
31.1 mg/L), 5.2% (l-SFLC; mean: 56.6 mg/L), 7.9% (k-SFLC;
mean: 15.9 mg/L), 7.3% (k-SFLC; mean: 29.3 mg/L), 12.5%
(SFLC-ratio low concentrations; mean: 0.52) and 8.1% (SFLC-
ratio high concentrations; mean: 0.52).
Standard work-up
The standard work-up included SPE, IFE with pentavalent
antiserum and analysis of k- and l-SFLC. SPE was performed
to provide follow-up for the requesting physician. If screen-
ing with pentavalent antiserum indicated the presence of
monoclonal protein, monospecific IFE (for specificities, see
above) was performed.
If using monospecific IFE a monoclonal band against k
and/or l without associated heavy chain was detected, a
Bence Jones protein or a monoclonal IgD or IgE was
assumed. Because Bence Jones proteins are more common,
a Bence Jones IFE was performed first. If there was no evi-
dence of the presence of Bence Jones protein in peripheral
blood, further testing against D and ´ heavy chains using IFE
was performed.
Data analysis
Patient clinical information was obtained from the hospital
information system. Calculations were performed using
Analyse-it (Analyse-it Software, Ltd., Leeds, UK) and Excel
(Microsoft, Unterschleissheim, Germany).
Results
Test performance of increased k-/l-SFLC
concentrations and SFLC-ratio for the detection
of monoclonal protein by IFE
Sensitivity and specificity for increased k- or l-SFLC
concentrations, or an abnormal ratio for the detection
of monoclonal protein by IFE indicating PCD wmono-
clonal gammopathy of undetermined significance
(MGUS), multiple myeloma, Waldenström macroglo-
bulinaemia, monoclonal light-chain (AL) amyloidosisx
was evaluated in 690 patients (one patient with IgA
but no detectable light chain by IFE was excluded).
The patients included 196 (30%) with intact immuno-
globulins and 18 (2.6%) patients with Bence Jones
protein as diagnosed with Bence Jones IFE (Table 1).
The sensitivity of an increased k-SFLC for the detec-
tion of monoclonal proteins by IFE was 82%, while
Böer and Deufel: Evaluation of screening algorithms for monoclonal gammopathies 1111
Article in press - uncorrected proof
Table 1 Sensitivity and specificity of increased k-SFLC and increased SFLC-ratio for the detection of monoclonal proteins by
IFE involving the k light chain (intact immunoglobulin or FLC), increased l-SFLC and decreased SFLC-ratio for the detection
of all for the detection of monoclonal proteins by IFE involving the l light chain (intact immunoglobulin or FLC) and combined
abnormal SFLC-ratio (-0.26 or )1.65) for the detection of any monoclonal protein (intact or FLC).
Sensitivity Specificity Positive predictive Negative predictive
value value
k-SFLC )19.4 mg/L 0.82 0.48 0.24 0.93
l-SFLC )26.3 mg/L 0.58 0.66 0.22 0.91
k/l-ratio )1.65 0.52 0.94 0.65 0.91
k/l-ratio -0.26 0.31 0.99 0.88 0.9
Combined abnormal ratio 0.41 0.96 0.79 0.9
-0.26 and )1.65
SFLC, serum free light chain; IFE, immunofixation; FLC, free light chain.
Table 2 k-, l-SFLC concentrations and SFLC-ratios in patients with IFE confirmed by monoclonal gammopathy (intact immu-
noglobulin or FLC) and patients with oligoclonal patterna (3 or more low-level bands) by IFE.
IFE result No. No. of abnormal No. of abnormal
k, % ratio, %
IgG-k 79 62 (78) 39 (49)
IgA-k 13 12 (92) 10 (77)
IgM-k 18 15 (83) 5 (28)
k-Light chain 9 9 (100) 9 (100)
No. of abnormal l, % No. of abnormal ratio, %
IgG-l 68 36 (53) 14 (21)
IgA-l 9 5 (56) 3 (33)
IgM-l 6 4 (67) 1 (17)
IgD-l 3 3 (100) 3 (100)
l-Light chain 9 9 (100) 9 (100)
No. of abnormal k, % No. of abnormal l, % No. of abnormal ratio, %
Negative 426 221 (52) 146 (34) 20 (5)
Oligoclonala 50 38 (76) 29 (58) 8 (16)
IgA (non-reactive 1 1 0 0
with k or l)
SFLC, serum free light chain; IFE, immunofixation; FLC, free light chain.
sensitivity of increased l-SFLC, decreased or increas-
ed ratio and abnormal l-SFLC ratio were 58%, 31%,
52% and 41%, respectively. The specificity of an
abnormal SFLC-ratio was 96%, 48% for increased k-
SFLC and 66% for increased l-SFLC in the detection
of monoclonal proteins by IFE. All k- and l-light chain
diseases were detected with the SFLC immunoassay
(Table 2). The positive predictive value (PPV) for the
detection of PCD was 79% for an abnormal ratio.
Abnormal SFLC concentrations occurred in patients
with oligoclonal IFE results (Table 2) and abnormal
ratios were detected in eight patients. Abnormal SFLC
concentrations were found in patients with intact,
monoclonal k- and l- immunoglobulins (Table 2).
Overall, 51 of 215 patients were positive by IFE only.
Among the 426 patients negative by IFE, 52% and 34%
had increased k and/ or l SFLC concentration, respec-
tively, but with a normal SFLC-ratio.
Patients with abnormal SFLC-ratios
and negative IFE
Eighteen patients with abnormal SFLC-ratios but neg-
ative monospecific and Bence Jones IFE were detect-
ed and classified as equivocal (Figure 1, Table 3). Two
samples with an abnormal ratio but normal individual
SFLC were excluded because the patient history was
not consistent with monoclonal gammopathy. One of
these patients was admitted for psychiatric disease,
the other was admitted for diabetes mellitus and renal
insufficiency. Concentrations of SFLC were, in most
cases, below the detection limit of the Bence Jones
IFE (150 mg/L). Therefore, monoclonality could not be
proven. Four of the patients had SFLC-ratios -0.26,
indicating a shift towards l-SFLC, while the other
ratios were )1.65 indicating a shift towards k-SFLC.
Nine of these patients suffered from haematological
disorders including chronic lymphatic leukaemia
(CLL) and other lymphomas. Other patients were
diagnosed with autoimmune disorders including
rheumatic arthritis and systemic lupuserythematosus,
inflammatory processes and non-haematological
tumours. In one patient (patient 14), increased SFLC
resulted in bone marrow biopsy, which was negative.
In four patients, increased plasma creatinine concen-
trations were detected and two patients were diag-
nosed with renal insufficiency.
One patient (patient 16, Table 3) presented with
renal insufficiency attributed to type 2 diabetes mel-
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Figure 1 Flow chart of the results of the plasma cell dyscrasias (PCD) screening programme in serum including immunofix-
ation (IFE) (monospecific and Bence Jones) and measurement of serum free light chain (SFLC) in 691 patients.
IFEq indicates that IFE was positive and a monoclonal protein was detected, SFLCq indicates that k- and/or l-SLFC were
abnormal, SFLC k/lq indicates that the SFLC-ratio was abnormal.
Table 3 Summary of SFLC-concentrations, SFLC-ratio, creatinine concentration in serum and clinical diagnosis in 18 patients
with negative monospecific and negative Bence Jones IFE, but abnormal SFLC-ratios (-0.26 or )1.65).
Patient k-SFLC, l-SFLC, k/l-ratio Monospecific Clinical diagnosis (bone Creatinine, mol/L
no. mg/L mg/L and Bence Jones marrow biopsy was (individual reference
IFE result performed if indicated) range)
1 -10 164 -0.06 Negative CLL 112 (72–127)
2 -10 58.3 -0.17 Negative CLL 109 (72–127)
3 -10 43.4 -0.23 Negative CLL 138 (72–127)
4 13 52.7 0.25 Negative Systemic lupus erythematosus 61 (58–96)
5 54.3 32.4 1.68 Negative Rheumatoid arthritis, renal 157 (72–127)
insufficiency
6 34.1 19.8 1.72 Negative Renal insufficiency, 319 (72–127)
inflammatory process
7 23.8 12 1.98 Negative Unknown 97 (72–127)
8 26.9 13.4 2.01 Negative Epileptic seizure 93 (58–96)
9 20.9 -10 )2.09 Negative CLL 97 (72–127)
10 21.2 -10 )2.12 Negative CLL 99 (72–127)
11 26.2 10.5 2.50 Negative Diffuse large B-cell-lymphoma 147 (58–96)
12 25.1 -10 )2.51 Negative Prostate cancer 67 (72–127)
13 26.5 -10 )2.65 Negative Angiosarcoma. Diabetes mellitus 121 (72–127)
14 79.5 -10 )3.02 Negative LCMM suspected (Negative bone 87 (72–127)
marrow biopsy)
15 137 -10 )13.70 Negative Mantle cell lymphoma 83 (72–127)
16 659 37.2 17.72 Negative Amyloidosis (negative bone marrow 436 (58–96)
biopsy but positive kidney biopsy)
17 753 12.1 62.23 Negative k-Light chain myeloma (positive 104 (72–127)
bone marrow biopsy)
18 4830 47.7 101.26 Negative k-Light chain myeloma (positive 686 (58–96)
bone marrow biopsy)
If bone marrow biopsies were performed they are indicated in the clinical diagnosis section. Patients with later proven light
chain disease are in bold font. SFLC, serum free light chain; IFE, immunofixation; CLL, chronic lymphatic leukaemia; LCMM,
light-chain multiple myeloma.
litus and amyloidosis was suspected following renal
biopsy. Bone marrow biopsy revealed no abnormali-
ties. One patient (patient 18, Table 3) presented with
nausea, weight loss, exhaustion and a plasma creat-
inine of 914 mmol/L, indicative of renal insufficiency.
A bone marrow biopsy following the result of mono-
clonal screening confirmed the diagnosis of LCMM.
One patient (patient 17, Table 3) presented with
weight loss, exhaustion, bone pain and fever in a
peripheral hospital and was transferred for further
diagnostic procedures. Bone marrow biopsy con-
firmed the diagnosis of LCMM. Serum and urine from
patients 16 and 18 was subjected to further investi-
gations. Serum was found negative by a second
Bence Jones IFE (Titan Gel Immunofixation, Helena,
Beaumont, TX, USA). In addition, Bence Jones IFE
from urine was negative, although increased concen-
trations of k-SFLC were detected by the ‘‘Freelite’’
assay. Serum and urine from patient 17 was not
investigated further.
Increased k-/l-SFLC concentrations )150 mg/L
in patients negative by Bence Jones IFE
Eleven patients with k and three patients with l light
chain concentrations above 150 mg/L were negative
by Bence Jones IFE, although the SFLC-ratio indicated
the presence of monoclonal Bence Jones protein
(Table 4). This group also included patients 16–18
described above. All other patients had monoclonal,
intact immunoglobulin using monospecific IFE. In
most cases, the other light chain was within the nor-
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Table 4 Summary of SFLC-concentrations, SFLC-ratio, result of monovalent IFE and clinical diagnosis from 11 patients with
negative Bence Jones IFE but either k- or l-SFLC )150 mg/L (theoretical cut-off of Bence Jones IFE).
Patient k-SFLC, l-SFLC, Ratio Monospecific Bence-Jones- Clinical diagnosis
no. mg/L mg/L IFE result IFE result
19 1960 -10 )196 IgA-k Negative IgA-k myeloma
20 1370 -10 )137 IgG-k Negative IgG-k myeloma
21 740 14.1 52.5 IgG-k Negative IgG-k myeloma
22 592 24.3 24.4 IgG-k Negative Acute cardiac decompensation
(no further PCD work-up, follow-up lost)
23 413 22 18.8 IgG-k Negative IgG-k myeloma
24 400 18.3 21.9 IgG-k Negative IgG-k myeloma
25 173 46.6 3.7 IgG-k Negative Negative bone marrow biopsy 2 years
earlier, IgG-k myeloma 2 years later
26 160 46.8 3.4 IgM-l Negative Acute cardiac decompensation
(no further PCD work-up, follow-up lost)
27 -10 2440 -0.004 IgA-l Negative IgG-l myeloma
28 -10 371 -0.027 IgG-l Negative IgG-l myeloma
29 18.4 293 0.06 IgG-l Negative IgG-l myeloma
Patients 16–18 from Table 3 (SFLC concentrations )150 mg/L and negative by Bence Jones IFE) are not repeatedly listed.
SFLC, serum free light chain; IFE, immunofixation; PCD, plasma cell dyscrasias.
Figure 2 Flow chart breaking down the results of the mod-
ified screening procedure in terms of SPEq (pronounced
hypogammaglobulinaemia, suspected monoclonal band)
and/or SFLCq wincreased SFLC concentrations (one or both)x
and/or SFLC k/lq (abnormal k-/l-SFLC-ratio).
IFE results from all patients are listed in the lower part and
separated by a dashed line.
mal range. In two patients, detection of the mono-
clonal protein did not result in a further work-up were
lost to follow-up.
Performance of a modified serum only screening
procedure
The performance of a modified work-up, similar to
that recently suggested by Piehler et al. (11), was
analysed retrospectively. Similar to the procedure
described, pentavalent IFE would have been per-
formed only if abnormalities were detected by SPE
(pronounced hypogammaglobulinaemia, suspected
M-protein band) or if k-, l-SFLC concentrations or the
SFLC-ratio were abnormal. Using this approach, 180
fewer pentavalent IFEs would have been performed
(26%) (Figure 2).
However, two of these patients and one other
patient, identified as having no abnormality on SPE,
normal SFLC concentrations and ratio, were found to
have a monoclonal protein by IFE. All monoclonal
bands that were detected were of weak intensity, but
clearly visible.
Discussion
Screening for monoclonal gammopathies in the rou-
tine diagnostic laboratory did, until recently, include
analysis of serum and urine (1, 2). Following the intro-
duction of a commercially available automated assay
for the detection and quantitation of SFLC, a more
simplified strategy, avoiding the frequently forgotten,
time-consuming collection of urine and work-up has
been evaluated (7, 10–12, 16). While intact monoclo-
nal immunoglobulins are usually detected by the
presence of an M-protein band on SPE, increased con-
centrations of SFLC and/or abnormal ratios suggests
the presence of monoclonal light-chain disease. When
intact monoclonal proteins are present in serum,
SFLC may be produced in excess, accompanying
heavy-chain bound FLC of the same type. The sensi-
tivity and specificity of increased k- and l-SFLC for
the detection of monoclonal proteins was lower than
reported previously (8), although the percentage of
sera with abnormal SFLC-ratios among the individu-
als with monoclonal gammopathies was comparable
to the percentage quoted in another study (8). The
PPV was moderately higher for ratios -0.26, and
clearly higher for ratios )1.65 compared to that
reported by Hill et al. (7). For the combined abnormal
ratio (-0.26; )1.65) results were comparable to that
reported by Vermeersch et al. (16) in similar hospital
populations. Differences in assay performance for the
prediction of positive IFE (intact immunoglobulin or
FLC) may be due to differences in patient populations
that are analysed because specificity of any assay will
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increase if pre-test probability increases, as is the
case when using serum from patients with IIMM only.
All LCMM where detected using the ‘‘Freelite’’
assay. All patients with IgD-l IIMM had very high
SFLC concentrations, a fact also described by Mead
et al. (18).
In general, the clinical use of SFLC quantitation in
the work-up of PCD largely depends on careful pre-
selection of patients. If the pre-test probability is low,
a situation often occurring in unselected patient
populations, increased FLC concentrations in individ-
uals should be interpreted with care because several
clinical conditions may cause this finding (17, 19–21).
If no other symptoms point toward the diagnosis of a
PCD, performing a time-consuming, onerous PCD
work-up might not be reasonable. However, abnormal
SFLC-ratios are very specific for monoclonal gam-
mopathies, and a diagnostic follow-up including addi-
tional diagnostic investigations should be considered.
Among the patients with abnormal SFLC-ratios and
negative Bence Jones IFE, haematological disorders
dominated with CLL being the most frequent diag-
nosis. These conditions have been correlated with
increased SFLC concentrations (22–24) and it appears
to be a common feature associated with haematolo-
gical disorders. Among the remaining patients,
inflammation and kidney disease were notable and
these two conditions have been associated with
increased SFLC concentrations (17, 19–21). In the case
of patients with kidney insufficiency, wider reference
ranges have been recently suggested (17). In our
study, four patients received further diagnostic work-
up due to an increased SFLC ratio despite a negative
IFE, resulting in the detection of PCD in three cases.
When interpreting abnormal SFLC-ratios, one should
consider along with concentrations of the SFLC, renal
function, presence of inflammatory disease and the
IFE result. Also, imprecision of the assay needs to be
considered since the calculation of the ratio depends
on the imprecision of two parameters. Patients with
minimally elevated or decreased ratios may have nor-
mal ratios when samples are assayed repeatedly, or
assayed with different reagent lots or with a different
analyser (20, 25). Considering these limitations, the
SFLC-ratio may provide a very specific parameter for
the detection of PCD in IFE-negative patients. How-
ever, the patient population used in this study was too
small to derive a cut-off ratio, which would prompt
further diagnostic procedures, such as bone marrow
biopsy or bone scan.
In 14 patients, markedly increased concentrations
of either k- or l-SFLC were measured, without detect-
ing monoclonal bands by Bence Jones IFE. Increased
SFLC concentrations with negative IFE primarily
affected patients with increased k-SFLC. Most of these
patients presented with a monoclonal, intact immu-
noglobulin using monospecific IFE, a condition fre-
quently accompanied by excessive SFLC production.
Overestimation of SFLC concentrations is a common-
ly described problem when measuring SFLC in serum
(20). Therefore, some of the Bence Jones proteins
detected in these patients might not be detectable by
IFE because the ‘‘true’’ SFLC concentration was lower
than that measured in the SFLC assay. In some
patients with very high SFLC concentrations, it is
more likely that the antiserum did not bind the respec-
tive light chain or that polymerisation of FLC (26)
resulted in a negative IFE. However, monitoring SFLC
in patients with intact immunoglobulins and
increased SFLC might be important because renal
involvement is detected in a high percentage of
patients with multiple myeloma (27), which may be
caused by the light chain component of the disease.
This is especially underscored by the fact that renal
involvement was found in 100% of all patients with
monoclonal IgD-protein. This study and another
found monoclonal IgD-protein associated with very
high SFLC concentrations (19). Bence Jones IFE was
negative and SFLC concentrations were high in two
patients later diagnosed with LCMM (Table 3, patients
17 and 18) and one patient with AL (Table 3, patient
16). In the patients with LCMM, measurement of SFLC
provided a useful complement for the work-up of PCD
because, compared to other diagnostic procedures, it
is less expensive and less onerous for the patient. In
the patient with AL, it supported the diagnosis that
was suspected following kidney biopsy. However, in
patients with suspected AL, analysis of urine should
always be included because of its higher sensitivity
(15).
Recently, a modified work-up has been proposed
and we retrospectively tested the performance of this
work-up in our patient population. In contrast to
Piehler et al. (11), SFLC were assayed in all patient
samples because information from clinicians and
from the hospital information system are impractical
to obtain and might be inaccurate. Using this setting,
three patients were missed who were diagnosed with
intact monoclonal protein using IFE. We showed that
not all patients with intact monoclonal proteins in
serum produce SFLC in excess resulting in normal or
almost normal SFLC concentrations and a normal
ratio. In addition, monoclonal peaks of the IgM-type
may be covered by the IgG-fraction in the g globulin
fraction and peaks of the IgA-type may be covered by
the b globulin fraction in the SPE. Also, peaks of the
IgG-type may not be discovered by SPE. In contrast
to the result by Piehler et al. (11), three patients with
intact monoclonal immunoglobulins by IFE were not
detected in the modified screening procedure.
Although the clinical significance of these findings
has been questioned (7, 12), insufficient information
on these patients was available to the laboratory to
determine the clinical relevance. The laboratory
should supply all available information with careful
interpretation and consultation with the haematolo-
gist is recommended to decide on further laboratory
and clinical investigations. If, for example, MGUS is
diagnosed based on these results, there is an
increased risk for the developing malignancy and
these patients should be monitored regularly (28).
If IFE of serum is omitted from the screening pro-
cedure, the sensitivity of screening will decrease
because cases with normal SFLC concentrations and
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ratios the detection of intact monoclonal immuno-
globulins relies solely on SPE, and monoclonal pro-
teins may not be visible in all cases. Therefore, IFE
should be a part of the screening procedure for mono-
clonal proteins.
Limitations of this study were that Bence Jones IFE
in urine was not part of the general screening pro-
gramme. Although there is evidence that screening
serum only is sufficient to detect all patients with clin-
ically relevant PCD, screening of serum and urine is
still considered the gold standard and therefore not
all patients with PCD might have been detected.
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